Weightstry review

Weightstry and Fitstry are two different purchase arrangements

Weightstry presents a women’s practice focused on perimenopause, while Fitstry is its GLP-1-focused route. The distinction matters financially. Fitstry advertises plans from $249 per four weeks for the shorter commitment, with certain care components temporarily included, rather than a separate practice membership automatically added to every medication purchase.

The lower $149 semaglutide and $199 tirzepatide cards concern longer-plan offers. They do not establish flexible four-week rates, and a shorter-plan tirzepatide amount is not itemized publicly. Obtain a drug-specific quote and full commitment rather than assigning the general $249 program floor to every molecule or assuming the lowest card describes the same arrangement.

Four-week billing and temporary inclusions need explicit terms

Fitstry says plans bill and medication ships every four weeks. That means thirteen cycles over 52 weeks on an uninterrupted recurring schedule, rather than twelve calendar-month charges. Confirm the amount due for the chosen prescription and the next billing date before comparing it with a plan that genuinely renews monthly.

Its limited-time offer includes visits, laboratory services and coaching without separate care charges, described as medication-only payment. Ask what those inclusions cover and when the offer ends. A temporary inclusion should not be treated as a permanent guarantee that every future clinical service is free. The agreement should explain how treatment changes affect both the medication and the included care.

The practice membership is a separate budget

Weightstry’s broader practice advertises a $150 monthly charter membership or $405 quarterly, with medication priced separately by the pharmacy at approximately $249–$339 monthly. It also states a later public membership rate of $347. The charter page still displays a July 20, 2026 closing date or a member limit, so current eligibility for that older offer needs confirmation.

Do not assume the charter rate remains available simply because the page remains visible, or add it to Fitstry’s separate offer without checking which program is selected. The practice describes access to obesity-medicine care, an OB-GYN, a registered dietitian and a moderated forum. Ask which professionals and contacts are actually included in the purchased membership.

A women’s focus has a defined scope

The perimenopause emphasis is relevant to a reader wanting weight and hormonal concerns discussed together. It does not establish that menopause causes an individual’s weight change or that every patient needs hormone treatment. The clinician should explain the assessment and any proposed additional therapy separately from the marketing focus.

The public material does not set out dedicated postpartum, breastfeeding or PCOS guidance. Ask how the team addresses the patient’s actual circumstances and coordinates with existing care. The presence of an OB-GYN is an identifiable service feature, but it should lead to a clear conversation about scope and access rather than an assumption that every reproductive-health need is covered.

Keep refund promises attached to the right program

Fitstry describes a full first-payment refund if a licensed clinician does not approve treatment. Weightstry’s practice policies separately describe membership and clinical-fit refund conditions. Those are specific promises with different triggers, not a general right to return dispensed medication or unwind every longer-term purchase. Obtain the agreement governing the actual route selected.

The published footprint has Louisiana waitlisted within a 49-state service claim. Confirm current access, the treating practice and dispensing pharmacy before relying on a plan. Weightstry may interest someone comparing a focused medication program with a broader perimenopause practice, but the choice depends on the actual four-week quote or membership-plus-medication total. Those are distinct commitments whose terms matter more than the smallest advertised monthly equivalent.